Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) CFO William J. Peters sold 6,226 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $19.67, for a total value of $122,465.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Amphastar Pharmaceuticals, Inc. (AMPH) traded down $0.35 on Thursday, reaching $18.33. The company’s stock had a trading volume of 131,300 shares, compared to its average volume of 292,800. The firm has a market capitalization of $842.74, a P/E ratio of 124.53 and a beta of 1.69. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.08 and a quick ratio of 1.86. Amphastar Pharmaceuticals, Inc. has a 12-month low of $12.05 and a 12-month high of $21.75.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Wednesday, November 8th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.02 by $0.05. The company had revenue of $57.90 million for the quarter, compared to analysts’ expectations of $57.23 million. Amphastar Pharmaceuticals had a return on equity of 2.30% and a net margin of 0.12%. The firm’s revenue was down 9.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.14 earnings per share. research analysts predict that Amphastar Pharmaceuticals, Inc. will post -0.03 earnings per share for the current fiscal year.
Amphastar Pharmaceuticals declared that its board has initiated a stock buyback plan on Wednesday, August 9th that authorizes the company to repurchase $20.00 million in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 2.8% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board believes its shares are undervalued.
A number of research firms have weighed in on AMPH. Needham & Company LLC upped their target price on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the stock a “buy” rating in a research report on Friday, December 1st. BMO Capital Markets upped their target price on Amphastar Pharmaceuticals from $16.00 to $17.00 and gave the stock a “market perform” rating in a research report on Friday, November 10th. Raymond James Financial downgraded Amphastar Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $18.00 target price for the company. in a research report on Thursday, November 9th. Jefferies Group set a $19.00 target price on Amphastar Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, October 29th. Finally, Zacks Investment Research downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 27th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $20.86.
Several hedge funds and other institutional investors have recently bought and sold shares of the business. GSA Capital Partners LLP bought a new position in shares of Amphastar Pharmaceuticals in the third quarter valued at $400,000. Argent Capital Management LLC increased its holdings in shares of Amphastar Pharmaceuticals by 102.6% in the third quarter. Argent Capital Management LLC now owns 121,275 shares of the company’s stock valued at $2,167,000 after buying an additional 61,425 shares in the last quarter. Cornerstone Capital Management Holdings LLC. increased its holdings in shares of Amphastar Pharmaceuticals by 1.8% in the third quarter. Cornerstone Capital Management Holdings LLC. now owns 283,200 shares of the company’s stock valued at $5,060,000 after buying an additional 5,000 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Amphastar Pharmaceuticals by 17.0% in the third quarter. Dimensional Fund Advisors LP now owns 1,558,113 shares of the company’s stock valued at $27,844,000 after buying an additional 226,271 shares in the last quarter. Finally, Nordea Investment Management AB increased its holdings in shares of Amphastar Pharmaceuticals by 11.6% in the third quarter. Nordea Investment Management AB now owns 129,046 shares of the company’s stock valued at $2,306,000 after buying an additional 13,439 shares in the last quarter. 44.14% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This story was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://ledgergazette.com/2017/12/07/william-j-peters-sells-6226-shares-of-amphastar-pharmaceuticals-inc-amph-stock.html.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.